Innovative Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Pneumonia with Carrimycin: A Case Report.
Ann Clin Lab Sci
; 54(4): 558-562, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-39293847
ABSTRACT
Carbapenem-resistant Pseudomonas aeruginosa is a common multidrug-resistant bacterium encountered in clinical practice. This pathogen causes pneumonia, which is difficult to treat owing to the limited choice of antimicrobial drugs, resulting in a relatively high mortality rate. Carrimycin is a new macrolide antibiotic with broad-spectrum antibacterial and potential immunomodulatory effects. Herein, we report a case of severe pneumonia caused by carbapenem-resistant Pseudomonas aeruginosa that presented with septic shock and Acute Respiratory Distress Syndrome (ARDS). Initially, we used piperacillin-tazobactam and ceftazidime-avibactam but without satisfactory results. Finally, we administered carrimycin in combination with piperacillin-tazobactam; the patient's condition improved, and he was successfully weaned off the ventilator. Therefore, the combined use of carrimycin should be considered for patients infected with carbapenem-resistant Pseudomonas aeruginosa who do not respond to conventional anti-infection treatments.
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pseudomonas aeruginosa
/
Pseudomonas Infections
/
Carbapenems
/
Anti-Bacterial Agents
Limits:
Aged
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Clin Lab Sci
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
Estados Unidos